Health
GSK’s gonorrhoea drug hits major target in late-stage trial
British drugmaker GSK said its oral drug to treat gonorrhoea has achieved a key goal of staying ahead of existing combination drugs in late-stage trials.
Roche’s Xolar reduces severe food allergy reactions in study
Xolar, an asthma drug marketed 20 years ago by Roche and Novartis significantly reduced allergic reactions in people with multiple severe food allergies in a
U.S. new drug prices up 35% in 2023
Pharmaceutical companies last year launched new drugs in the U.S. at prices 35% higher than in 2022, partly reflecting the industry’s use of expensive treatments
EU medicines regulator backs Biogen’s ALS drug
The European medicines regulator on Friday recommended granting Biogen’s registration certificate to a drug for the deadly and progressive neurodegenerative disease known as amyotrophic lateral
South Korean hospitals extend working hours to cope with doctors’ protest
South Korea’s public hospitals will extend their working hours while expanding the use of telemedicine to ease growing pressure on health services following a mass
United Therapeutics begins litigation with FDA over rival Liquidia’s drug application
United Therapeutics said Wednesday it has filed a lawsuit with the U.S. Food and Drug Administration, alleging that proper procedures were not followed to allow
GSK’s injectable HIV drug is more promising
British drugmaker GSK said Wednesday that its long-acting injectable HIV therapy showed promising results in maintaining a suppressed viral load compared with daily oral treatment,
Indian drug companies develop versions of Wegovy
Indian drug companies have started developing their own versions of Novo Nordisk’s Wegovy. With some analysts predicting that the weight loss market will reach $100
More than half the world faces a high risk of contracting measles
More than half of the world’s countries will be at high or very high risk of measles outbreaks by the end of the year unless
Johnson & Johnson’s blood cancer drug has received US FDA approval
The US Food and Drug Administration has approved Johnson & Johnson’s biweekly dose of Tecvayli blood cancer therapy. The approval allows the therapy to be